In this study, antiproliferative effects of the anti-EGFR monoclonal antibody Cetuximab were
evaluated using MDA-MB-231 cell line originated from triple negative breast cancer. As cell
kinetic parameters, we evaluated Cell index, mitotic index, labeling index and apoptotic index.
For this purpose, 20 μM, 45 μM and 60 μM Cetuximab concentrations were applied to the
cells using the real-time cell analysis system (xCelligence DP) and IC50 values were
determined. IC50 concentrations were used for all other parameters. According to
experimental results, Cetuximab administration inhibited cell kinetics of MDA-MB-231 cells.
xCelligence DP instrument detected IC50 concentrations of Cetuximab for cell line. These
values were 45 μM for MDA-MB-231 cells. When these IC50 value applied to cells,
significant decrease was detected in mitotic index, labelling index and significant increase was
detected in apoptotic index for experimental groups. Student’s t tests for paired samples were
used to assign statistical significance. p<0.05 level of significance was accepted. According to
the results obtained, Cetuximab has the potential to slow down the prognosis of the triple
negative breast cancer subtype.